[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100402145":3},{"organization":4,"armGroups":7,"interventions":35,"overallOfficials":47,"centralContacts":65,"locations":71,"responsibleParty":302,"collaborators":47,"id":304,"slug":47,"hasResults":305,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":309,"eligibilityCriteria":310,"healthyVolunteers":305,"sex":311,"minAge":312,"maxAge":47,"enrollmentInfo":313,"targetDuration":47,"studyType":316,"phases":317,"briefSummary":319,"conditions":320,"keywords":325,"overallStatus":74,"whyStopped":47,"lastUpdateSubmitDate":326,"lastUpdatePostDateStruct":327,"startDateStruct":330,"completionDateStruct":332,"leadSponsor":334,"locationsCount":335},{"fullName":5,"class":6},"K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc","INDUSTRY",[8,15,20,25,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Part 1: Azenosertib + carboplatin","EXPERIMENTAL","Azenosertib in combination with carboplatin",[13,14],"Drug: Azenosertib","Drug: Carboplatin",{"label":16,"type":10,"description":17,"interventionNames":18},"Part 1: Azenosertib + PLD","Azenosertib in combination with pegylated liposomal doxorubicin (PLD)",[13,19],"Drug: Pegylated liposomal doxorubicin",{"label":21,"type":10,"description":22,"interventionNames":23},"Part 1: Azenosertib + paclitaxel","Azenosertib in combination with paclitaxel",[13,24],"Drug: Paclitaxel",{"label":26,"type":10,"description":27,"interventionNames":28},"Part 1: Azenosertib + gemcitabine","Azenosertib in combination with gemcitabine",[13,29],"Drug: Gemcitabine",{"label":31,"type":10,"description":32,"interventionNames":33},"Part 2: Azenosertib + bevacizumab","Azenosertib in combination with bevacizumab",[13,34],"Biological: Bevacizumab",[36,43,48,52,56,60],{"type":37,"name":38,"description":39,"armGroupLabels":40,"otherNames":41},"DRUG","Azenosertib","Investigational drug",[16,9,26,21,31],[42],"ZN-c3",{"type":37,"name":44,"description":45,"armGroupLabels":46,"otherNames":47},"Carboplatin","Carboplatin is an approved drug",[9],null,{"type":37,"name":49,"description":50,"armGroupLabels":51,"otherNames":47},"Pegylated liposomal doxorubicin","Pegylated liposomal doxorubicin (PLD) is an approved drug",[16],{"type":37,"name":53,"description":54,"armGroupLabels":55,"otherNames":47},"Paclitaxel","Paclitaxel is an approved drug",[21],{"type":37,"name":57,"description":58,"armGroupLabels":59,"otherNames":47},"Gemcitabine","Gemcitabine is an approved drug",[26],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":47},"BIOLOGICAL","Bevacizumab","Bevacizumab is an approved drug",[31],[66],{"name":67,"role":68,"phone":69,"phoneExt":47,"email":70},"K-Group, Beta, Inc., a subsidiary of Zentalis Pharmaceuticals","CONTACT","8582634333","medicalaffairs@zentalis.com",[72,85,95,105,114,124,134,145,155,166,175,185,195,201,211,221,230,239,249,258,268,278,287,296],{"facility":73,"status":74,"city":75,"state":76,"zip":77,"country":78,"cosmosGeoPoint":79,"geoPoint":84,"contacts":47},"Site 0264","RECRUITING","Aurora","Colorado","80045","United States",{"type":80,"coordinates":81},"Point",[82,83],-104.83192,39.72943,{"lat":83,"lon":82},{"facility":86,"status":74,"city":87,"state":88,"zip":89,"country":78,"cosmosGeoPoint":90,"geoPoint":94,"contacts":47},"Site 0104","Boston","Massachusetts","02215",{"type":80,"coordinates":91},[92,93],-71.05977,42.35843,{"lat":93,"lon":92},{"facility":96,"status":74,"city":97,"state":98,"zip":99,"country":78,"cosmosGeoPoint":100,"geoPoint":104,"contacts":47},"Site 0111","St Louis","Missouri","53110",{"type":80,"coordinates":101},[102,103],-90.19789,38.62727,{"lat":103,"lon":102},{"facility":106,"status":74,"city":107,"state":107,"zip":108,"country":78,"cosmosGeoPoint":109,"geoPoint":113,"contacts":47},"Site 0173","New York","10029",{"type":80,"coordinates":110},[111,112],-74.00597,40.71427,{"lat":112,"lon":111},{"facility":115,"status":74,"city":116,"state":117,"zip":118,"country":78,"cosmosGeoPoint":119,"geoPoint":123,"contacts":47},"Site 0259","Durham","North Carolina","27710",{"type":80,"coordinates":120},[121,122],-78.89862,35.99403,{"lat":122,"lon":121},{"facility":125,"status":74,"city":126,"state":127,"zip":128,"country":78,"cosmosGeoPoint":129,"geoPoint":133,"contacts":47},"Site 0191","Providence","Rhode Island","02905",{"type":80,"coordinates":130},[131,132],-71.41283,41.82399,{"lat":132,"lon":131},{"facility":135,"status":136,"city":137,"state":138,"zip":139,"country":78,"cosmosGeoPoint":140,"geoPoint":144,"contacts":47},"Site 0196","COMPLETED","Nashville","Tennessee","37203",{"type":80,"coordinates":141},[142,143],-86.78444,36.16589,{"lat":143,"lon":142},{"facility":146,"status":74,"city":147,"state":148,"zip":149,"country":78,"cosmosGeoPoint":150,"geoPoint":154,"contacts":47},"Site 0103","Houston","Texas","77030",{"type":80,"coordinates":151},[152,153],-95.36327,29.76328,{"lat":153,"lon":152},{"facility":156,"status":136,"city":157,"state":158,"zip":159,"country":160,"cosmosGeoPoint":161,"geoPoint":165,"contacts":47},"Site 2707","South Brisbane","Queensland","4101","Australia",{"type":80,"coordinates":162},[163,164],153.02049,-27.48034,{"lat":164,"lon":163},{"facility":167,"status":136,"city":168,"state":158,"zip":169,"country":160,"cosmosGeoPoint":170,"geoPoint":174,"contacts":47},"Site 2708","Sunshine Coast","4556",{"type":80,"coordinates":171},[172,173],153.07955,-26.65682,{"lat":173,"lon":172},{"facility":176,"status":136,"city":177,"state":178,"zip":179,"country":160,"cosmosGeoPoint":180,"geoPoint":184,"contacts":47},"Site 2709","Adelaide","South Australia","5000",{"type":80,"coordinates":181},[182,183],138.59863,-34.92866,{"lat":183,"lon":182},{"facility":186,"status":74,"city":187,"state":188,"zip":189,"country":160,"cosmosGeoPoint":190,"geoPoint":194,"contacts":47},"Site 2716","Melbourne","Victoria","3121",{"type":80,"coordinates":191},[192,193],144.96332,-37.814,{"lat":193,"lon":192},{"facility":196,"status":74,"city":187,"state":188,"zip":197,"country":160,"cosmosGeoPoint":198,"geoPoint":200,"contacts":47},"Site 2706","3144",{"type":80,"coordinates":199},[192,193],{"lat":193,"lon":192},{"facility":202,"status":74,"city":203,"state":204,"zip":205,"country":160,"cosmosGeoPoint":206,"geoPoint":210,"contacts":47},"Site 2705","Nedlands","Western Australia","6009",{"type":80,"coordinates":207},[208,209],115.8073,-31.98184,{"lat":209,"lon":208},{"facility":212,"status":136,"city":213,"state":47,"zip":214,"country":215,"cosmosGeoPoint":216,"geoPoint":220,"contacts":47},"Site 1001","Banja Luka","78000","Bosnia and Herzegovina",{"type":80,"coordinates":217},[218,219],17.20629,44.77879,{"lat":219,"lon":218},{"facility":222,"status":136,"city":223,"state":47,"zip":224,"country":215,"cosmosGeoPoint":225,"geoPoint":229,"contacts":47},"Site 1002","Sarajevo","71000",{"type":80,"coordinates":226},[227,228],18.35644,43.84864,{"lat":228,"lon":227},{"facility":231,"status":136,"city":232,"state":47,"zip":233,"country":215,"cosmosGeoPoint":234,"geoPoint":238,"contacts":47},"Site 1003","Tuzla","75000",{"type":80,"coordinates":235},[236,237],18.66709,44.53842,{"lat":237,"lon":236},{"facility":240,"status":136,"city":241,"state":47,"zip":242,"country":243,"cosmosGeoPoint":244,"geoPoint":248,"contacts":47},"Site 1202","Panagyurishte","4500","Bulgaria",{"type":80,"coordinates":245},[246,247],24.19021,42.49518,{"lat":247,"lon":246},{"facility":250,"status":136,"city":251,"state":47,"zip":252,"country":243,"cosmosGeoPoint":253,"geoPoint":257,"contacts":47},"Site 1201","Sofia","1632",{"type":80,"coordinates":254},[255,256],23.32415,42.69751,{"lat":256,"lon":255},{"facility":259,"status":136,"city":260,"state":47,"zip":261,"country":262,"cosmosGeoPoint":263,"geoPoint":267,"contacts":47},"Site 1401","Tbilisi","0112","Georgia",{"type":80,"coordinates":264},[265,266],44.83412,41.69143,{"lat":266,"lon":265},{"facility":269,"status":136,"city":270,"state":47,"zip":271,"country":272,"cosmosGeoPoint":273,"geoPoint":277,"contacts":47},"Site 1902","Belgrade","11080","Serbia",{"type":80,"coordinates":274},[275,276],20.46513,44.80401,{"lat":276,"lon":275},{"facility":279,"status":136,"city":280,"state":47,"zip":47,"country":281,"cosmosGeoPoint":282,"geoPoint":286,"contacts":47},"Site 2901","Busan","South Korea",{"type":80,"coordinates":283},[284,285],129.03004,35.10168,{"lat":285,"lon":284},{"facility":288,"status":136,"city":289,"state":47,"zip":290,"country":281,"cosmosGeoPoint":291,"geoPoint":295,"contacts":47},"Site 2903","Seoul","03080",{"type":80,"coordinates":292},[293,294],126.9784,37.566,{"lat":294,"lon":293},{"facility":297,"status":136,"city":289,"state":47,"zip":298,"country":281,"cosmosGeoPoint":299,"geoPoint":301,"contacts":47},"Site 2904","05505",{"type":80,"coordinates":300},[293,294],{"lat":294,"lon":293},{"type":303,"investigatorFullName":47,"investigatorTitle":47,"investigatorAffiliation":47,"oldNameTitle":47,"oldOrganization":47},"SPONSOR","100402145",false,"NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer","A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer","MUIR","INCLUSION CRITERIA:\n\nFor Part 1:\n\n* Histologically or cytologically confirmed FIGO Stage III\u002FIV high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal carcinoma.\n* Subjects must have received 1 or 2 prior therapeutic regimens\u002Flines of therapy in the advanced or metastatic setting. At least one regimen must have contained cisplatin or carboplatin.\n* The disease must be platinum resistant (ie, the PFI must have been \\\u003C 6 months). Platinum refractory disease (ie, PD during first-line platinum-based therapy) is allowed.\n\nFor Part 2 Dose Escalation:\n\nPrior therapy:\n\n• Subjects must have received 6 cycles of platinum-based doublet chemotherapy in the 1L or 2L setting as their most recent therapy\n\nResponse to prior platinum therapy:\n\n1. In the 1L setting: Complete Response, Partial Response, or Stable Disease to platinum-based chemotherapy.\n2. In the 2L setting:\n\n   1. Progressive Disease \\>183 days after receiving the last dose of platinum chemotherapy in the 1L setting,\n   2. Complete Response, Partial Response, or Stable Disease to 2L platinum-based chemotherapy.\n\n      * Adequate hematologic, and organ function\n\nFor Part 2 Dose Expansion:\n\n* Subjects must have at least 4 cycles of platinum-based chemotherapy in 2L and have Complete Response, Partial Response, or Stable Disease\n* Subjects must have progressed while on a PARP inhibitor for 1L maintenance Additional protocol-defined inclusion criteria may apply\n\nEXCLUSION CRITERIA:\n\n* Histology of abdominal adenocarcinoma of unknown origin or diagnosis of a borderline ovarian tumor.\n* Subjects with carcinosarcomas (even if there is a serous component)\n* A serious illness or medical condition(s)\n* Subjects with active (uncontrolled, metastatic) second malignancies or requiring therapy.\n\nAdditional protocol-defined exclusion criteria may apply","FEMALE","18 Years",{"count":314,"type":315},172,"ESTIMATED","INTERVENTIONAL",[318],"PHASE1","This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of azenosertib (ZN-c3) in combination with other drugs.",[321,322,323,324],"Solid Tumor","Epithelial Ovarian Cancer","Fallopian Tube Cancer","Peritoneal Cancer",[321],"2026-04-01",{"date":328,"type":329},"2026-04-07","ACTUAL",{"date":331,"type":329},"2020-10-26",{"date":333,"type":315},"2028-06-30",{"name":5,"class":6},24]